Skip to main content

Advertisement

SpringerLink
Log in

Liver injury during rivaroxaban treatment in a patient with AL amyloidosis

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Song AB, Rosovsky RP, Connors JM, Al-Samkari H (2019) Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. Vasc Health Risk Manag 15:175–186. Published 2019 Jun 21. https://doi.org/10.2147/VHRM.S132556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Grandoni F, Alberio L (2019) Direct oral anticoagulant drugs: on the treatment of cancer-related venous thromboembolism and their potential anti-neoplastic effect. Cancers (Basel) 11(1):46. Published 2019 Jan 5. https://doi.org/10.3390/cancers11010046

    Article  CAS  Google Scholar 

  3. Al-Samkari H, Connors JM (2018) The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel) 10(8):271. Published 2018 Aug 15. https://doi.org/10.3390/cancers10080271

    Article  CAS  Google Scholar 

  4. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624. https://doi.org/10.1056/nejmoa1711948

    Article  CAS  PubMed  Google Scholar 

  5. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497. https://doi.org/10.1161/circulationaha.108.785014

    Article  CAS  PubMed  Google Scholar 

  6. European Association for the Study of the Liver (2019) EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 70:1222–1261

    Article  Google Scholar 

  7. Teschke R (2019) Idiosyncratic DILI: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019. Front Pharmacol 23:730

    Article  Google Scholar 

  8. Bjornsson HK, Gudmundsson DO, Bjornsson ES Liver injury caused by oral anticoagulants: a population-based retrospective cohort study. Liver Int 40(8):1895–1900. https://doi.org/10.1111/liv.14559

  9. Yuan L, Kaplowitz N (2013) Mechanisms of drug-induced liver injury. Clin Liver Dis 17(4):507–518. https://doi.org/10.1016/j.cld.2013.07.002

    Article  PubMed  PubMed Central  Google Scholar 

  10. Samiei F, Sajjadi H, Jamshidzadeh A, Seydi E, Pourahmad J (2019) Contrasting role of concentration in rivaroxaban induced toxicity and oxidative stress in isolated kidney mitochondria. Drug Res (Stuttg). 69(10):523–527

    Article  CAS  Google Scholar 

  11. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J (2014) Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 100(7):550–556. https://doi.org/10.1136/heartjnl-2013-305288

    Article  CAS  PubMed  Google Scholar 

  12. Watkins PB, Desai M, Berkowitz SD et al (2011) Evaluation of drug-induced serious hepatotoxicity (eDISH). Drug-Safety 34:243–252. https://doi.org/10.2165/11586600-000000000-00000

    Article  PubMed  Google Scholar 

  13. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Rivaroxaban. [Updated 2018 Feb 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548015/

  14. Peverelle M, Asadi K, Sinclair M (2018) Drug-induced liver failure due to rivaroxaban. Ann Hematol. https://doi.org/10.1007/s00277-018-3364-z

  15. Liakoni E, Rätz Bravo AE, Krähenbühl S (2015) Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf 38:711–720. https://doi.org/10.1007/s40264-015-0317-5

    Article  CAS  PubMed  Google Scholar 

  16. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA (2014) Rivaroxaban postmarketing risk of liver injury. J Hepatol. https://doi.org/10.1016/j.jhep.2014.03.026

  17. Baig M, Wool KJ, Halanych JH, Sarmad RA (2015) Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci. 7(9):407–410. https://doi.org/10.4103/1947-2714.166221

    Article  PubMed  PubMed Central  Google Scholar 

  18. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver (2002) Larrey D Semin Liver Dis. 22(2):145–155

    Article  Google Scholar 

  19. Shin YM (2011) Hepatic amyloidosis. Korean J Hetatol 17(1):80–83. https://doi.org/10.3350/kjhep.2011.17.1.80

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Beaumont Hospital, Dublin 9, Ireland

    Alan Marrinan, L. Shackleton, C. Kelly, M. Lavin, S. Glavey, P. Murphy & J. Quinn

  2. Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland

    M. Lavin

  3. Department of Medicine, RCSI, Dublin, Ireland

    S. Glavey, P. Murphy & J. Quinn

Authors
  1. Alan Marrinan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Shackleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lavin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Glavey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.M., L.S., and C.K. collected the data. A.M. and J.Q. analyzed the data. All authors (A.M, L.S., C.K., M.L., S.G., P.M, J.Q.) were involved in writing and reviewing the article.

Corresponding author

Correspondence to Alan Marrinan.

Ethics declarations

Conflict of interest

The authors declare that they have no relevant conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marrinan, A., Shackleton, L., Kelly, C. et al. Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. Eur J Clin Pharmacol 77, 1073–1076 (2021). https://doi.org/10.1007/s00228-020-03084-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-03084-8

Search

Navigation